The steady-state pharmacokinetics in serum and urine of the enantiomers of citalopram and its metabolites, demethylcitalopram (DCT) and didemethylcitalopram (DDCT), were investigated after multiple doses of rac-citalopram for 21 consecutive days (40 mg per day) to healthy human subjects who were ext
Steady-state pharmacokinetics of diltiazem and hydrochlorothiazide administered alone and in combination
โ Scribed by Scott J. Weir; Dan C. Dimmitt; Robert C. Lanman; M. Bruce Morrill; Dennis H. Geising
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 159 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0142-2782
No coin nor oath required. For personal study only.
โฆ Synopsis
Diltiazem and hydrochlorothiazide are widely used to treat cardiovascular disease, often in combination. The purpose of this investigation was to determine whether a drug -drug pharmacokinetic interaction exists between diltiazem and hydrochlorothiazide. In a randomized, crossover, open study, multiple doses of diltiazem (60 mg four times daily for 21 doses) and hydrochlorothiazide (25 mg twice daily for 11 doses) were administered alone and in combination on three separate occasions to 20 healthy male volunteers. Trough and serial blood samples were collected and plasma was assayed for diltiazem, hydrochlorothiazide, and diltiazem metabolites (desacetyldiltiazem and N-desmethyldiltiazem) using HPLC. Total urine was also collected and quantified for hydrochlorothiazide.
Coadministered hydrochlorothiazide did not significantly (p \0.05) alter diltiazem (alone versus combination) steady-state maximum plasma concentration (C ss max ; 145 versus 158 ng mL -1 , respectively), time to maximum plasma concentration (t max ; 3.0 versus 2.8 h, respectively); area under the plasma concentration-time curve (AUC ss ; 688 versus 771 ng โข h mL -1 ), oral clearance (Cl oral ; 96.2 versus 88.0 L h -1 ), or elimination half-life (t 1/2 ; 5.2 versus 5.2 h). Similarly, administration of diltiazem did not significantly (p\0.05) influence hydrochlorothiazide (alone versus combination) C ss max (221 versus 288 ng mL -1 ), t max (1.8 versus 2.0 h), AUC ss (1194 versus 1247 ng โข h mL -1 ), Cl oral (22.4 versus 21.2 L h -1 ); t 1/2 (9.8 versus 9.6 h), or renal Cl (15.5 versus 15.2 L h -1 ). In conclusion, a clinically significant pharmacokinetic interaction between diltiazem and hydrochlorothiazide does not exist.
๐ SIMILAR VOLUMES
In the present study we investigated the enantioselectivity in the pharmacokinetics of metoprolol administered in a multiple-dose regimen as the racemate. The study was conducted on 10 patients of both sexes with mild to severe essential hypertension, aged 28 to 76 years, with normal hepatic and ren
Two carbamazepine (CBZ) tablet formulations (conventional, CBZ-CO, or controlled release, CBZ-CR) are commonly prescribed in monotherapy or in comedication with phenobarbital (PB) in the treatment of epilepsies. This study compares the pharmacokinetics of CBZ-CO against CBZ-CR in patients with epile
The single-dose and steady state pharmacokinetics of butorphanol and its metabolites, hydroxybutorphanol (HO-B) and norbutorphanol (NOR-B), were studied in nine healthy male volunteers. Each subject received a single 1 mg dose of butorphanol on days 1 and 6, and a 1 mg dose every 6 h (q6h) on days 2
This study was conducted to determine the relative bioavailability of Dilacorm XR capsules compared to CardizemD CD capsules at both low (180mgdPL) and high (540mgd-') dose levels. Trough and serial plasma samples were obtained and pharmacokinetic parameters were calculated from the steady state con
The effect of food on the pharmacokinetics of BMS-181101, a new anti-depressant under development, was investigated in 12 healthy male volunteers at steady state. Each subject received a 15 mg oral dose of BMS-181101 twice a day (q 12 h) for 11 days and a morning dose of BMS-181101 on day 12. Six su